$119.24
2.07% yesterday
Nasdaq, Nov 20, 10:00 pm CET
ISIN
IE00B4Q5ZN47
Symbol
JAZZ

Jazz Pharmaceuticals Plc Stock price

$119.24
+6.12 5.41% 1M
+10.62 9.78% 6M
-3.76 3.06% YTD
-1.41 1.17% 1Y
-10.18 7.87% 3Y
-21.41 15.22% 5Y
-50.60 29.79% 10Y
Nasdaq, Closing price Wed, Nov 20 2024
+2.42 2.07%
ISIN
IE00B4Q5ZN47
Symbol
JAZZ
Sector
Industry

Key metrics

Market capitalization $7.21b
Enterprise Value $10.79b
P/E (TTM) P/E ratio 17.17
EV/FCF (TTM) EV/FCF 9.55
EV/Sales (TTM) EV/Sales 2.70
P/S ratio (TTM) P/S ratio 1.81
P/B ratio (TTM) P/B ratio 1.73
Revenue growth (TTM) Revenue growth 5.23%
Revenue (TTM) Revenue $3.99b
EBIT (operating result TTM) EBIT $738.08m
Free Cash Flow (TTM) Free Cash Flow $1.13b
Cash position $2.62b
EPS (TTM) EPS $6.94
P/E forward 14.22
P/S forward 1.79
EV/Sales forward 2.67
Short interest 7.92%
Show more

Is Jazz Pharmaceuticals Plc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Jazz Pharmaceuticals Plc Stock Analysis

Unlock Scores for Free

Analyst Opinions

20 Analysts have issued a Jazz Pharmaceuticals Plc forecast:

16x Buy
80%
4x Hold
20%

Analyst Opinions

20 Analysts have issued a Jazz Pharmaceuticals Plc forecast:

Buy
80%
Hold
20%

Financial data from Jazz Pharmaceuticals Plc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
3,993 3,993
5% 5%
100%
- Direct Costs 1,044 1,044
4% 4%
26%
2,949 2,949
9% 9%
74%
- Selling and Administrative Expenses 699 699
1% 1%
18%
- Research and Development Expense 860 860
7% 7%
22%
1,389 1,389
16% 16%
35%
- Depreciation and Amortization 651 651
4% 4%
16%
EBIT (Operating Income) EBIT 738 738
30% 30%
18%
Net Profit 463 463
479% 479%
12%

In millions USD.

Don't miss a Thing! We will send you all news about Jazz Pharmaceuticals Plc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Jazz Pharmaceuticals Plc Stock News

Positive
Reuters
about 10 hours ago
The U.S. Food and Drug Administration approved Jazz Pharmaceuticals' drug, zanidatamab-hrii, for the treatment of a type of biliary tract cancer, the company said on Wednesday.
Neutral
PRNewsWire
about 10 hours ago
Ziihera is the first and only dual HER2-targeted bispecific antibody approved for HER2+ BTC in the U.S. Ziihera received accelerated approval based on results including a 52% objective response rate and median duration of response of 14.9 months as determined by independent central review (ICR) from the HERIZON-BTC-01 clinical trial Company to host investor webcast on Dec. 11, 2024 For U.S. med...
Neutral
PRNewsWire
one day ago
DUBLIN , Nov. 19, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in Citi's 2024 Global Healthcare Conference. Company management will participate in a fireside chat on Tuesday, December 3, 2024, at 7:15 a.m.
More Jazz Pharmaceuticals Plc News

Company Profile

Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: XYREM, ERWINAZETM, PRIALT, intrathecal infusion, FAZACLO and LUVOX CR. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Head office Ireland
CEO Bruce Cozadd
Employees 2,800
Founded 2005
Website www.jazzpharmaceuticals.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today